Respiratory distress syndrome of newborn. Hyaline membrane disease
Conditions
Interventions
Intervention 1: In intervention group one dose of 12 mg Betamethasone 4 mg/ml from Abouraihan Pharmaceutical Company will be injected via intramuscular injection. Intervention 2: In control group two
Treatment - Drugs
In intervention group one dose of 12 mg Betamethasone 4 mg/ml from Abouraihan Pharmaceutical Company will be injected via intramuscular injection.
In control group two doses of 12 mg Betamethasone 4 mg/ml from Abouraihan Pharmaceutical Company with the interval of 24 hours will be injected via intramuscular injection.
Sponsors
Vice Chancellor for Research, Kurdistan University of Medical Sciences
Eligibility
Sex/Gender
Female
Age
15 Years to 45 Years
Inclusion criteria
Inclusion criteria: Inclusion criteria were singleton pregnancy and gestational age 26- 34 weeks Exclusion criteria included: allergy to Betamethasone, history of any maternal systemic disorders like hypertension, diabetes, liver and cardiac disease, renal failure, neoplasia and cervical dilation > 5 cm.
Exclusion criteria
Exclusion criteria:
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Respiratory distress syndrome. Timepoint: Every day up to 28 days after birth. Method of measurement: sign and symptoms of Respiratory distress syndrome diagnosed by pediatrician. | — |
Secondary
| Measure | Time frame |
|---|---|
| Intraventricular Hemorrhage. Timepoint: Every day up to 28 days after birth. Method of measurement: Clinical examination by pediatrician.;Infant Death. Timepoint: Every day up to 28 days after birth. Method of measurement: Based on neonatologist diagnosis.;Necrotizing enterocolitis. Timepoint: Every day up to 28 days after birth. Method of measurement: Clinical examination by pediatrician. | — |
Countries
Iran (Islamic Republic of)
Contacts
Public ContactFereshte Seymari
Kurdistan University of Medical Sciences
Outcome results
None listed